Literature DB >> 26730844

Prevalence, incidence, risk factors and treatment of atrial fibrillation in Australia: The Australian Diabetes, Obesity and Lifestyle (AusDiab) longitudinal, population cohort study.

Ibrahima Diouf1, Dianna J Magliano2, Melinda J Carrington3, Simon Stewart3, Jonathan E Shaw2.   

Abstract

OBJECTIVE: We sought to describe the prevalence, incidence, risk factors and treatment (according to stroke risk) of atrial fibrillation (AF) in the national, population-based Australian Diabetes, Obesity and Lifestyle (AusDiab) study cohort.
METHODS: ECG data were available from 8273/11,247 participants of AusDiab study in 1999/2000 and from 5422 participants in 2004/2005. Minnesota coding was used to identify prevalent and incident cases of AF.
RESULTS: 90 prevalent cases of AF (14.1 per 1000) comprising 56 men (mean age 70.5 ± 1.9 years) and 34 women (aged 78.3 ± 1.2 years) were identified in 1999-2000. AF prevalence was associated with sedentary behaviour versus physically active (PR 2.0, 95% CI 1.2-3.6). 53 incident cases of AF (2.0, 95%, CI 1.5-2.6 per 1000 person-year) were subsequently identified in 2004-2005. Increased risk of incident AF was associated with male sex, obesity, history of angina, myocardial infarction and stroke. Both increased weight gain and increased weight loss appeared to be associated with increased risks of developing AF in women, while no obvious association was observed in men. Despite their high risk for stroke, anti-thrombotic therapy was observed in only 39.3% of participants with CHA2DS2-VASC scores ≥ 2.
CONCLUSIONS: This study contributes to a better understanding of the AF burden. With the ageing population, coordinated efforts will be needed to anticipate the future health care costs related to AF and its impacts on the health care system. This will include appropriate application of anti-thrombotic therapy according to risk of thrombo-embolic events.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Epidemiology risk factors; Incidence; Prevalence; Risk factors; Treatments

Mesh:

Year:  2015        PMID: 26730844     DOI: 10.1016/j.ijcard.2015.12.013

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.

Authors:  Laila Staerk; Jason A Sherer; Darae Ko; Emelia J Benjamin; Robert H Helm
Journal:  Circ Res       Date:  2017-04-28       Impact factor: 17.367

Review 2.  Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  Dagfinn Aune; Abhijit Sen; Sabrina Schlesinger; Teresa Norat; Imre Janszky; Pål Romundstad; Serena Tonstad; Elio Riboli; Lars J Vatten
Journal:  Eur J Epidemiol       Date:  2017-02-13       Impact factor: 8.082

3.  Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis.

Authors:  Nicholas R Jones; Kathryn S Taylor; Clare J Taylor; Paul Aveyard
Journal:  Heart       Date:  2019-06-22       Impact factor: 5.994

4.  Weight, height, weight change, and risk of incident atrial fibrillation in middle-aged men and women.

Authors:  Cecilia Johansson; Marcus M Lind; Marie Eriksson; Lars Johansson
Journal:  J Arrhythm       Date:  2020-07-23

5.  The Canadian Occupational Performance Measure (COPM) as Routine Practice in Community-Based Rehabilitation: A Retrospective Chart Review.

Authors:  Glade Vyslysel; Daniel Barker; Isobel J Hubbard
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-05-24

6.  Using electronic medical record data to assess chronic kidney disease, type 2 diabetes and cardiovascular disease testing, recognition and management as documented in Australian general practice: a cross-sectional analysis.

Authors:  Julia L Jones; Natalie G Lumsden; Koen Simons; Anis Ta'eed; Maximilian P de Courten; Tissa Wijeratne; Nicholas Cox; Christopher J A Neil; Jo-Anne Manski-Nankervis; Peter Shane Hamblin; Edward D Janus; Craig L Nelson
Journal:  Fam Med Community Health       Date:  2022-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.